Statistics for Trial in Progress of Engot-Cx8/Gog-3024/Innovatv 205: Addition of A New Cohort Using First-Line Tisotumab Vedotin Plus Pembrolizumab Plus Carboplatin +/- Bevacizumab in Recurrent/Metastatic Cervical Cancer

Total visits

views
Trial in Progress of Engot-Cx8/Gog-3024/Innovatv 205: Addition of A New Cohort Using First-Line Tisotumab Vedotin Plus Pembrolizumab Plus Carboplatin +/- Bevacizumab in Recurrent/Metastatic Cervical Cancer 0

Total visits per month

views
August 2025 0
September 2025 0
October 2025 0
November 2025 0
December 2025 0
January 2026 0
February 2026 0

File Visits

views
ae30.pdf 4